Tue, Sep 2, 2014, 4:35 PM EDT - U.S. Markets closed

Recent

% | $
Quotes you view appear here for quick access.

Amicus Therapeutics, Inc. (FOLD) Message Board

vvvvvvrebel89130 1627 posts  |  Last Activity: 10 minutes ago Member since: Sep 15, 2008
SortNewest  |  Oldest  |  Highest Rated Expand all messages
  • i know they're hedging with calls but still there's a point when they have to cover; some of these shorts are under from back in june when the stock was in the 3's

    8/15/2014 15,348,087 4,625,697 3.318005

    Sentiment: Strong Buy

  • Reply to

    124,466 @ $12.77 at the buzzer

    by vvvvvvrebel89130 34 minutes ago
    vvvvvvrebel89130 vvvvvvrebel89130 12 minutes ago Flag

    yep; we got that sorted out and the right price, lol

    no way this traded over 10mm shrs on a ubs upgrade

    there's more to this, a lot more

    Sentiment: Strong Buy

  • Reply to

    124,466 @ $12.77 at the buzzer

    by vvvvvvrebel89130 34 minutes ago
    vvvvvvrebel89130 vvvvvvrebel89130 20 minutes ago Flag

    amazing, scottrade doesn't show either

    here's what nas shows that ties to the scott number

    16:00:00 $ 12.27 62,233

    no filings either; i think maybe a filing is coming?

    Sentiment: Strong Buy

  • Reply to

    124,466 @ $12.77 at the buzzer

    by vvvvvvrebel89130 34 minutes ago
    vvvvvvrebel89130 vvvvvvrebel89130 26 minutes ago Flag

    duh, lol; i'm posting under the influence

    12.31 crossing now

    Sentiment: Strong Buy

  • Reply to

    124,466 @ $12.77 at the buzzer

    by vvvvvvrebel89130 34 minutes ago
    vvvvvvrebel89130 vvvvvvrebel89130 33 minutes ago Flag

    12.57; sorry guys

    Sentiment: Strong Buy

  • vvvvvvrebel89130 by vvvvvvrebel89130 34 minutes ago Flag

    124k at the close at the high

    i likey

    Sentiment: Strong Buy

  • Reply to

    7-day data for P-1

    by quishayk 4 hours ago
    vvvvvvrebel89130 vvvvvvrebel89130 1 hour 17 minutes ago Flag

    suspect now they present both results together; just like the update where both trials were updated on the same pr; seems like their mo

    will probably get a triple header as they might announce the start of the combo trial which is promised i think to be completed by year end

    Sentiment: Strong Buy

  • vvvvvvrebel89130 by vvvvvvrebel89130 1 hour 19 minutes ago Flag

    pretty amazing

    Sentiment: Strong Buy

  • Reply to

    7-day data for P-1

    by quishayk 4 hours ago
    vvvvvvrebel89130 vvvvvvrebel89130 1 hour 31 minutes ago Flag

    the 6 week 3102 trial started in mid aug; should be due in late oct-nov?

    Sentiment: Strong Buy

  • SippinCoughy

    $ACHN CNBC mention

    Sentiment: Strong Buy

  • Reply to

    anyone who sells now all u can do is laugh

    by dikab50 1 hour 45 minutes ago
    vvvvvvrebel89130 vvvvvvrebel89130 1 hour 38 minutes ago Flag

    i've noticed that; i see vol jump on scottrade and i don't see the trades

    SKYNET!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!

    Sentiment: Strong Buy

  • vvvvvvrebel89130 vvvvvvrebel89130 1 hour 50 minutes ago Flag

    ubs and their clients are more than happy to buy up RA's sells in the mid 11's which is incredibly bullish.

    they're buying as much as they can at the 52 week which goes to your point that their asymetrical target of $15 is low balled

    Sentiment: Strong Buy

  • vvvvvvrebel89130 by vvvvvvrebel89130 2 hours 38 minutes ago Flag

    grass before the mower

    Sentiment: Strong Buy

  • vvvvvvrebel89130 by vvvvvvrebel89130 3 hours ago Flag

    bought

    Sentiment: Strong Buy

  • Reply to

    full ubs report

    by vvvvvvrebel89130 5 hours ago
    vvvvvvrebel89130 vvvvvvrebel89130 4 hours ago Flag

    The company has completed dosing of 1 mg/kg and 2 mg/kg dose cohorts. ARC-520 continues to be well tolerated, with no dropouts or serious adverse events reported. The overall rate of AEs has been lower in the
    top line results in 3rd qtr, which ends in 4 weeks

    might have been too optomistic about them being bought out but at some point both achn and arwr will be acquired; gut feeling more than anything else, but the value is with achn due to the nuc; only 3 in existence and 2 are locked up by gild and mrk

    arwr's pr sounds similar to achn's pr eh?
    gl

    Phase IIa than in the Phase I normal volunteer study and safety labs continue to show no indication of end organ toxicity.

    Initial blinded data suggest that the magnitude of HBsAg knockdown is similar to non-human primate studies, including the chronically infected chimpanzee reported on previously. Duration of knockdown appears to be substantially more sustained than in non-human primates, with patients in the 2 mg/kg group still demonstrating substantial knockdown after 8 weeks, which is the most recent time point available.

    HBsAg levels appear to continue to decline in a number of patients at the 8 week time point in the 2 mg/kg group.

    Based on the initial review, dosing less frequent than once monthly will be explored in Phase IIb.

    Due to the excellent safety profile of ARC-520, and because Arrowhead thought that ARC-520 could demonstrate even deeper knockdown of HBsAg, the company decided to explore 3 mg/kg in patients. The company has begun dosing that cohort. Arrowhead sees limited downside risk at this dose, because it completed a 3 mg/kg cohort in healthy volunteers and that safety profile was quite positive and consistent with all other groups tested.

    We are pleased to see that the trial remains on schedule to meet the previously stated goal of releasing top line results in the third quarter.

    Sentiment: Strong Buy

  • Reply to

    7-day data for P-1

    by quishayk 4 hours ago
    vvvvvvrebel89130 vvvvvvrebel89130 4 hours ago Flag

    june 10 - 3422 dosing begins
    aug 7 - 50mg & 150mg prelim results released; so to speak

    looks like it takes 1 mth per dose

    june - 50mg completed
    july 150mg completed

    aug - 300mg completed
    sept -500mg in progress and close

    is that right?

    Sentiment: Strong Buy

  • Reply to

    From Bloomberg news!

    by jagan1961 5 hours ago
    vvvvvvrebel89130 vvvvvvrebel89130 4 hours ago Flag

    this is how fly reported the ubs upgrade
    news worthy as fly says ubs thinks the results will be positive?

    not sure how fly got that from the ubs report, maybe there was more, don't know

    i don't think ubs goes out on a limb in front of trial results with an upgrade unless they're pretty darn sure the results are positive; and, as noted, ubs was on the bid all last week, so they're putting their money and their client's money where their mouth is

    Achillion price target raised to $15 from $11 at UBS
    UBS raised its price target on Achillion to $15 from $11 citing a positive risk/reward from the expected release of viral data this fall. The firm believes the data will be positive and will be used as a catalyst to drive potential M&A interest and keeps its Buy rating on the stock. Less Less

    Sentiment: Strong Buy

  • Reply to

    7-day data for P-1

    by quishayk 4 hours ago
    vvvvvvrebel89130 vvvvvvrebel89130 4 hours ago Flag

    here's my post on this from earlier; just a gut feeling, but i think something is coming very soon

    0 users liked this posts users disliked this posts 0
    Reply

    gut feeling; results are emminent
    by vvvvvvrebel89130 • 1 hour 46 minutes ago Remove

    this vol isn't because of the ubs upgrade; also, think ubs wanted to upgrade in front of the results

    Sentiment: Strong Buy

    Sentiment: Strong Buy

  • Reply to

    full ubs report

    by vvvvvvrebel89130 5 hours ago
    vvvvvvrebel89130 vvvvvvrebel89130 4 hours ago Flag

    oxgn is sitting on ovarian cancer results; binary disorder who posts here is also in it; hate to recommend it it's such a pain in the butt but has great potential; full results at a conference in austrailia in nov; put up or shut up; 32% pfs in top line results released in march; mgmt is incompetant if not crooked, huge short interest, outstanding warrants, most frustrating stock i've held; buyer beware, lol, but will end shortly;

    unxl is working on a new process for touch sensors; low float, huge short interest; they're supposed to go commercial this q

    arwr - no position but look at it; sister company of achn; same space, same dynamics; wish i had the money to buy a stake but i'll all in with the above; arwr might be bought before achn;

    i don't think ubs talked to achn ir; i think someone gave them the ok sign and it wasn't ir;

    Sentiment: Strong Buy

  • Reply to

    full ubs report

    by vvvvvvrebel89130 5 hours ago
    vvvvvvrebel89130 vvvvvvrebel89130 5 hours ago Flag

    mag, this is how fly reported the ubs story; i suspect ubs has talked with achn or has some hint

    Achillion price target raised to $15 from $11 at UBS
    UBS raised its price target on Achillion to $15 from $11 citing a positive risk/reward from the expected release of viral data this fall. The firm believes the data will be positive and will be used as a catalyst to drive potential M&A interest and keeps its Buy rating on the stock. Less

    Sentiment: Strong Buy

FOLD
6.97-0.22(-3.06%)4:00 PMEDT

Trending Tickers

i
Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.